Promising 2-year updated data from cadonilimab presented at 2023 ASCO highlighting promising efficacy in PD-L1-negative patients
WGN9,
HONG KONG, June 6, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") released two-year updated data from a Phase Ib/II…